41 – 50 of 81
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Diabetic patients with acute coronary syndromes in contemporary European registries : Characteristics and outcomes
(
- Contribution to journal › Article
-
Mark
Bivalirudin versus heparin monotherapy in myocardial infarction
(
- Contribution to journal › Article
-
Mark
Intravenous beta-blocker therapy in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention is not associated with benefit regarding short-term mortality : A Swedish nationwide observational study
(
- Contribution to journal › Article
-
Mark
Outcome of percutaneous coronary intervention with the Absorb bioresorbable scaffold : Data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
(
- Contribution to journal › Article
-
Mark
Intravascular Ultrasound Guidance is Associated with Better Outcome in Patients Undergoing Unprotected Left Main Coronary Artery Stenting Compared with Angiography Guidance Alone
(
- Contribution to journal › Article
- 2016
-
Mark
Sample Size in Clinical Cardioprotection Trials Using Myocardial Salvage Index, Infarct Size, or Biochemical Markers as Endpoint.
(
- Contribution to journal › Article
-
Mark
Automatic segmentation of myocardium at risk from contrast enhanced SSFP CMR: validation against expert readers and SPECT.
(
- Contribution to journal › Article
-
Mark
Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction - A registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial)
(
- Contribution to journal › Article
-
Mark
Multi-vendor, multicentre comparison of contrast-enhanced SSFP and T2-STIR CMR for determining myocardium at risk in ST-elevation myocardial infarction
(
- Contribution to journal › Article
-
Mark
Low real-world early stent thrombosis rates in ST-elevation myocardial infarction patients and the use of bivalirudin, heparin alone or glycoprotein IIb/IIIa inhibitor treatment : A nationwide Swedish registry report
(
- Contribution to journal › Article